Sonoma Biotherapeutics, a San Francisco, CA- and Seattle, WA-based clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, received a $45M investment from Regeneron Pharmaceuticals.
The company intends to use the funds to expand operations and its R&D sector.
Led by CEO Jeff Bluestone, Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system. It is employing proprietary platform technologies and approaches to develop a new generation of targeted and durable Treg cell therapies.
In March 2023, Sonoma Bio entered into a collaboration and license agreement with Regeneron to research, develop and commercialize Treg cell therapies for inflammatory bowel disease and two other undisclosed indications, with a Regeneron option for a fifth indication. The collaboration integrates Regeneron’s VelociSuite® technologies for the discovery and characterization of fully human antibodies and T cell receptors (TCRs) with Sonoma Bio’s approach to developing and manufacturing gene-modified Treg cell therapies.
Commenting on the news, Jeff Bluestone said: “The cutting-edge Regeneron technology for target identification and animal models, combined with Sonoma Bio’s Treg and cell therapy expertise, has enabled an effective collaboration in developing new treatment options for patients suffering from devastating autoimmune diseases.”
FinSMEs
04/09/2024